Sonidegib
Sonidegib (INN), sold under the brand name Odomzo, is a medication used to treat cancer.[1] Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism).[5][6] It was approved for medical use in the United States and in the European Union in 2015[7][1][8][9] It is indicated for the treatment of adults with locally advanced basal-cell carcinoma that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.Common side effects include muscle spasms, hair loss, fatigue, abdominal pain, nausea, headache, and weight loss.[1] It has been investigated as a potential treatment for: It has demonstrated significant efficacy against melanoma in vitro and in vivo.